Statins for Primary Prevention: Strategic Options to Save Lives and Money

Abstract

References

Gaw

, Packard

C.J.

At what level of coronary heart disease risk should a statin be prescribed?

Curr Opin Lipidol 2000; 11: 363–7

Jackson

P.R.

, Ramsay

L.E.

Debate: at what level of coronary heart disease risk should a statin be prescribed?

Curr Opin Lipidol 2000; 11: 357–61

Rose

Environmental health: problems and prospects.

J R Coll Physicians Lond 1991; 25: 48–52

Pyorala

, DeBacker

, Poole-Wilson

, Wood

, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121–61

Wood

, de Backer

, Faergeman

, Graham

, Mancia

, Pyorala

, together with members of the Task Force. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199–270

de Backer

, Ambrosioni

, Borch-Johnsen

. European guidelines on cardiovascular disease prevention in clinical practice. Europ J Cardiovasc Prev Rehab. 2003; 10: S1–S10

Executive summary of the third report of the NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).

JAMA 2001; 285: 2486–97

Stamler

, Wentworth

, Neaton

J.D.

Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

JAMA 1986; 256: 2823–8

West of Scotland Coronary Prevention Study Group.

Influence of pravastatin and plasma lipids on coronary events in the West of Scotland Coronary Prevention Study.

Circulation 1998; 97: 1440–5

10.

Sacks

F.M.

, Moye

L.A.

, Davis

B.R.

, Cole

T.G.

, Rouleau

J.L.

, Nash

D.T.

Relationship between plasma LDL cholesterol concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial (CARE).

Circulation 1998; 97: 1446–52

11.

Jones

, Kafonek

, Laurora

, Hunninghake

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study).

Am J Cardiol 1998; 81: 582–7

12.

National Service Framework for Coronary Heart Disease [www.doh.gov.uk/nsf/coronary.htm] accessed 12 December 2003

13.

Scottish Intercollegiate Guidelines Network. Lipids and the Primary Prevention of Coronary Heart Disease: SIGN, Publication No. 40. Edinburgh: Royal College of Physicians of Edinburgh, 1999

14.

Shepherd

, Cobbe

S.M.

, Ford

. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7

15.

Downs

J.R.

, Clearfield

, Weis

. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22

16.

Scandinavian Simvastatin Survival Study Group.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).

Lancet 1994; 344: 1383–9

17.

Sacks

F.M.

, Pfeffer

M.A.

, Moye

L.A.

. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9

18.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

N Engl J Med 1998; 339: 1349–57

19.

Serruys

P.W.

, de Feyter

, Macaya

. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215–22

20.

Heart Protection Study Collaborative Group.

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial.

Lancet 2002; 360: 7–22

21.

Shepherd

, Blauw

G.J.

, Murphy

M.B.

. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623–30

22.

Sever

P.S.

, Dahlof

, Poulter

N.R.

. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58

23.

The PPP Project Investigators.

Design, rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project: a combined analysis of three large-scale randomized trials: Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).

Am J Cardiol 1995; 76: 899–905